Show simple item record

dc.contributor.authorBlagden, Nicholas*
dc.contributor.authorde Matas, Marcel*
dc.contributor.authorGavan, Pauline T.*
dc.contributor.authorYork, Peter*
dc.date.accessioned2011-03-21T16:57:31Z
dc.date.available2011-03-21T16:57:31Z
dc.date.issued30/07/2007
dc.identifier.citationBlagden, N., De Matas, M., Gavan, P. T. and York, P. (2007). Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Advanced drug delivery reviews. Vol. 59, No. 7, pp. 617-630.en_US
dc.identifier.urihttp://hdl.handle.net/10454/4844
dc.descriptionnoen_US
dc.description.abstractThe increasing prevalence of poorly soluble drugs in development provides notable risk of new products demonstrating low and erratic bioavailabilty with consequences for safety and efficacy, particularly for drugs delivered by the oral route of administration. Although numerous strategies exist for enhancing the bioavailability of drugs with low aqueous solubility, the success of these approaches is not yet able to be guaranteed and is greatly dependent on the physical and chemical nature of the molecules being developed. Crystal engineering offers a number of routes to improved solubility and dissolution rate, which can be adopted through an in-depth knowledge of crystallisation processes and the molecular properties of active pharmaceutical ingredients. This article covers the concept and theory of crystal engineering and discusses the potential benefits, disadvantages and methods of preparation of co-crystals, metastable polymorphs, high-energy amorphous forms and ultrafine particles. Also considered within this review is the influence of crystallisation conditions on crystal habit and particle morphology with potential implications for dissolution and oral absorption.en_US
dc.language.isoenen_US
dc.subjectCrystal engineeringen_US
dc.subjectCrystallisationen_US
dc.subjectSupramolecular chemistryen_US
dc.subjectPolymorphismen_US
dc.subjectCo-crystalen_US
dc.subjectSolubilityen_US
dc.subjectDissolution rateen_US
dc.subjectBioavailabilityen_US
dc.subjectLow aqueous solubilityen_US
dc.titleCrystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.en_US
dc.status.refereedYesen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.1016/j.addr.2007.05.011


This item appears in the following Collection(s)

Show simple item record